In addition, IL-22 has been shown to promote PD-L1 expression through the activation of STAT3 (Wolk et al., 2010; Chen et al., 2019), and the anti-PD-L1 antibody nivolumab has been reported to be effective in bladder tumors with a high density of intratumoral IL22-producing cells (Zeng et al., 2020). This evidence concerns the gene STAT3 and urinary bladder neoplasm.